Sign in
INKT Stock Price, Chart, Stats & News
MiNK Therapeutics, Inc.
Save
62.27M
Market cap
–
Current P/E
–
Forward P/E
INKT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -82.57% |
ROE | 61.72% |
D/E | -0.42x |
Interest coverage ratio | – |
INKT valuation
P/E | – |
P/S | – |
P/B | -3.62x |
P/CF | -0.04x |
P/FCF | -0.04x |
P/OCF | -0.04x |
PEG | 0.67x |
EV multiple | -4.96x |
About
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction.
Similar securities
Based on sector and market capitalization
Report issue